Colorectal Liver Metastases: Current Management and Future Perspectives

Colorectal Liver Metastases: Current Management and Future Perspectives

Summary of Lecture by Dr. Sepideh Gholami, Northwell Health

1. Main Clinical Topics Discussed

• Epidemiology and unmet need in colorectal liver metastases (CRLM)
• Clinical and molecular prognostic factors governing surgical and oncologic decision-making
• Surgical resection criteria and outcomes
• Circulating tumor DNA (ctDNA) as an emerging biomarker
• Regional therapy via Hepatic Artery Infusion Pump (HAIP) for CRLM

2. Key Learning Points, Guidelines, and Recommendations

Surgical Resection Criteria ("ABCs"):

• Anatomical: Ability to achieve R0 resection with adequate future liver remnant; limited or absent extrahepatic disease
• Biology: Tumor molecular markers and response to chemotherapy
• Condition: Patient comorbidities, frailty, and performance status

Surgical Technique:

• Anatomic (segmental) resections are not superior to wedge resections, provided a negative margin is achieved
• Margin distance beyond negativity does not confer additional survival benefit — tumor biology is the dominant prognostic driver

Molecular Markers of Importance:

• RAS mutation: Associated with worse post-resection survival vs. wild-type
• TP53 + RAS co-mutation: Worse prognosis than single mutation alone
• BRAF mutation: BRAF wild-type patients demonstrate significantly better recurrence-free and overall survival post-hepatectomy
• Tumor sidedness:

- Right-sided primaries → worse survival

- Anti-EGFR therapy effective primarily in left-sided, RAS/BRAF wild-type disease

- Anti-VEGF therapy relatively more effective in right-sided disease

Hepatic Artery Infusion Pump (HAIP) Indications:

• Unresectable CRLM (with intent to convert to resectability)
• Adjuvant therapy post-hepatectomy to reduce recurrence
• Bridging therapy to liver transplantation in select patients

3. Specific Clinical Data, Statistics, and Study Results Cited

• Global burden: ~2 million new colorectal cancer cases estimated by 2020; second leading cause of cancer death worldwide
• Synchronous metastases: ~25% of patients present with liver metastases at diagnosis; an additional ~50% develop metastases during the disease course
• Upfront resectability: Only ~20% of CRLM patients are surgically resectable at presentation
• Post-resection recurrence: ≥70% recurrence rate even after curative-intent hepatectomy
• 5-year survival post-resection: 45–60% in contemporary series, including patients with multiple metastases
• 10-year disease-free survival (functional cure): ~20% of resected patients
• ctDNA post-resection: Detected in ~24% of patients; ctDNA positivity correlates with significantly higher recurrence rates vs. ctDNA-negative patients
• CALGB 9481 (HAIP vs. systemic therapy): 135 patients with unresectable CRLM randomized; HAIP with FUDR demonstrated significantly superior overall survival vs. systemic chemotherapy alone
• HAIP conversion trial (Phase 2): 64 patients with unresectable CRLM (median 13 tumor deposits; many heavily pre-treated); 81-month median follow-up; earlier pump placement associated with higher conversion-to-resection rates

4. Practical Takeaways for Clinicians

• Multidisciplinary molecular profiling is essential: RAS, BRAF, TP53, SMAD4, and tumor sidedness should be assessed in all CRLM patients to guide prognosis, systemic therapy selection, and surgical planning
• Surgical margin philosophy: Achieve R0 resection — wider margins beyond negativity do not improve outcomes; parenchymal preservation is preferred
• ctDNA integration: While not yet universal standard of care, ctDNA monitoring post-resection is a clinically useful tool to identify patients at high recurrence risk and guide adjuvant decision-making; further prospective validation